

DAFTAR PUSTAKA

1. Canonico ME, Santoro C, Avvedimento M, Giugliano G, Mandoli GE, Prastaro M, et al. Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. *Biomolecules*. 2022;12:1–14.
2. Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. *Cancers (Basel)*. 2020;12:1–11.
3. Leiva O, Newcomb R, Connors JM, Al-Samkari H. Cancer and thrombosis: new insights to an old problem. *JMV-Journal Médecine*. 2020;45:6S8–16.
4. Kurniawan A. Patogenesis, diagnosis, dan penatalaksanaan tromboemboli vena pada kanker. *Indones J Cancer [Internet]*. 2013;7:103–10. Available from: file:///C:/Users/HPP/Downloads/289-299-1-SM (2).pdf
5. Nadir Y. Heparanase and Coagulation—New Insights. *Rambam Maimonides Med J*. 2014;5:e0031.
6. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. *Clin Med Insights Oncol*. 2014;8:CMO-S18991.
7. Takahashi H, Ebihara S, Okazaki T, Suzuki S, Asada M, Kubo H, et al. Clinical significance of heparanase activity in primary resected non-small cell lung cancer. *Lung Cancer*. 2004;45:207–14.
8. Ikeda M, Uetake H, Yoshino T, Hata T, Oba MS, Takita A, et al. Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer-VTE Registry). *Cancer Sci*. 2022;113:3901.
9. Piccioli A, Falanga A, Baccaglioni U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. *Semin Thromb Hemost*. 2006;32:694–9.
10. Skinner N, Moran P. Deep vein thrombosis (DVT). *Case Management Society of America (CMSA)*; 2008.
11. Menon J, Hamilton G. Deep venous thrombosis. *Surg*. 2004;22:300–2.
12. Group JCSJW. Guidelines for the Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2009)—Digest Version—. *Circ J*. 2011;75:1258–81.
13. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodaysky I, et al. An ELISA method for the detection and quantification of human heparanase. *Biochem Biophys Res Commun*. 2006;341:958–63.

14. Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. *Cancer*. 2008;113:1004–11.
15. dos Santos TCF, Gomes AM, Paschoal MEM, Stelling MP, Rumjanek VM, do Rosário Junior A, et al. Heparanase expression and localization in different types of human lung cancer. *Biochim Biophys Acta (BBA)-General Subj*. 2014;1840:2599–608.
16. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. *Haematologica*. 2010;95:1927.
17. Nadir Y, Brenner B. Heparanase multiple effects in cancer. *Thromb Res* [Internet]. 2014;133:S90–4. Available from: [http://dx.doi.org/10.1016/S0049-3848\(14\)50015-1](http://dx.doi.org/10.1016/S0049-3848(14)50015-1)
18. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. *Eur Heart J*. 2018;39:4208–18.
19. Bonow RO, Mann DL, Zipes DP, Libby P. *Braunwald's Heart Disease: A text book of Cardiovascular Medicine* 2012. Saunderson Elsevier.
20. Turpie AGG, Chin BSP, Lip GYH. Venous thromboembolism: pathophysiology, clinical features, and prevention. *Bmj*. 2002;325:887–90.
21. Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiadi S. *Buku ajar ilmu penyakit dalam edisi VI*. Jakarta Pus Interna Publ. 2014;
22. Ali N, Mustafa B. Management of venous thrombo-embolism: From leeches to novel oral anticoagulants. *Ibnosina J Med Biomed Sci*. 2013;5:254–60.
23. Singh S, Pant S, Goje S, Gupta VK. UNDERSTANDING THE ETIOLOGY, DIAGNOSIS AND TREATMENT OF LUNG CANCER. *J Adv Sci Res*. 2022;13.
24. Waheed SM, Kudaravalli P, Hotwagner DT. *Deep vein thrombosis*. 2018;
25. Dávalos A, Castillo J. Potential mechanisms of worsening. *Cerebrovasc Dis*. 1997;7:19–24.
26. Putra DH, Wulandari L, Mustokoweni S. Profil penderita kanker paru karsinoma bukan sel kecil (KPKBSK) di RSUD Dr. Soetomo. *J Ilm Fak Kedokt Univ Airlangga*. 2016;8:30–4.

27. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. *Blood*. 2013;122:1873–80.
28. Nadir Y, Brenner B. Heparanase—A Link between Coagulation, Angiogenesis, and Cancer. *Rambam maimonides Med J*. 2012;3.
29. Bayam E, Kalçık M, Gürbüz AS, Yesin M, Güner A, Gündüz S, et al. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. *Thromb Res*. 2018;171:103–10.
30. Falanga A, Vignoli A. Venous thromboembolism in oncology. *Eksp Oncol*. 2004;26:11–4.
31. Tesselaar MET, Osanto S. Risk of venous thromboembolism in lung cancer. *Curr Opin Pulm Med*. 2007;13:362–7.
32. Harlivasari A, Syahrudin E. Hiperkoagulasi pada Kanker Paru. *J Respirologi Indones*. 2019;39:88–91.
33. Chen Y, Tsang YS, Chou X, Hu J, Xia Q. A lung cancer patient with deep vein thrombosis: A case report and literature review. *BMC Cancer*. 2019;19:4–9.
34. De Cicco M. The prothrombotic state in cancer: Pathogenic mechanisms. *Crit Rev Oncol Hematol*. 2004;50:187–96.
35. Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study. *Thromb Haemost*. 2017;117:57–65.
36. Canonico ME, Santoro C, Avvedimento M, Giugliano G, Mandoli GE, Prastaro M, et al. Venous thromboembolism and cancer: a comprehensive review from pathophysiology to novel treatment. *Biomolecules*. 2022;12:259.
37. Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al. The landscape of ALK-rearranged non-small cell lung cancer: A comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives. *Cancers (Basel)*. 2022;14:4765.
38. Zhang Y, Yang Y, Chen W, Guo L, Liang L, Zhai Z, et al. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. *Chest*. 2014;146:650–8.
39. Harlivasari AD, Syahrudin E. Hypercoagulation in Lung Cancer. *J Respirologi Indones*. 2019;39:130–9.

40. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. *J Cardiol* [Internet]. 2018;72:89–93. Available from: <https://doi.org/10.1016/j.jjcc.2018.02.011>
41. Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, et al. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. *iScience* [Internet]. 2019;15:360–90. Available from: <https://doi.org/10.1016/j.isci.2019.04.034>
42. Crispel Y, Axelman E, Tatour M, Kogan I, Nevo N, Brenner B, et al. Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model. *Thromb Haemost*. 2016;116:669–78.
43. Baker AB, Gibson WJ, Kolachalama VB, Golomb M, Indolfi L, Spruell C, et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. *J Am Coll Cardiol*. 2012;59:1551–60.
44. Alexander M, Kirsa S, Wolfe R, MacManus M, Ball D, Solomon B, et al. Thromboembolism in lung cancer—an area of urgent unmet need. *Lung Cancer*. 2014;84:275–80.
45. Gurbuz AS, Ozturk S, Efe SC, Yilmaz MF, Yanik RE, Yaman A, et al. Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction. *Biomarkers*. 2019;24:600–6.

